Clinical Trial Update: Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study of Tagraxofusp in patients with CD123+ or BPDCN-like acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tagraxofusp (tagraxofusp)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED